750 likes | 908 Views
Incidence of surgery after DES. 695 surgeries in 481 patients out of 12.794 with DES implantation (5.4%): Incidence as a function of time from intervention. Types of intervention. In 15 of 36 patients (42%) the event occurred right before or right after a surgical procedure
E N D
695 surgeries in 481 patients out of 12.794 with DES implantation (5.4%): Incidence as a function of time from intervention
In 15 of 36 patients (42%) the event occurred right before or right after a surgical procedure for which the 2 antiplatelet agents or Plavix alone was discontinued.
Timing of noncardiac surgery in cardiac-stable/ asymptomatic patients with prior PCI 2009 ESC Guidelines on perioperative evaluation for noncardiac surgery
October Early surgery after stent implantation: risk stratification for bleeding Colorectal surgery
Risk of early surgery after stent implantation * *All MACEs were fatal
Early surgery after stent implantation: High risk after discontinuation of dual antiplatelet therapy
550 patients undergoing non-cardiac surgery after stent implantation 35% 15% 13% 9% 6% MACE= death,MI,stent thrombosis,repeat revascularization
Noncardiac surgery after stent implantation: Antiplatelet therapy and risk of bleeding 550 patients undergoing non-cardiac surgery after stent implantation Van Kuijk P. Am J Cardiol 2009;104:1229
Early surgery after stent implantation: Decision making October
Ospedali Niguarda e Legnano PROTOCOLLO PER LA SOSPENSIONE TEMPORANEA DI CLOPIDOGREL PER CHIRURGIA NON-CARDIACA INDIFFERIBILE IN PAZIENTI PORTATORI DI STENT CORONARICO
Clopidogrel bridging protocol Inclusion criteria • Consecutive candidates for urgent major (CV or non-CV) surgery • or eye surgery in whom dual antiplatelet therapy could not be withdrawn as the time of surgery was within 6 months of the placement of any DES, or within one year of the placement of any DES under conditions considered to be at higher risk for stent thrombosis: • stent implantation due to an ACS, • diabetes, • renal insufficiency or • severe left ventricular dysfunction, • stents placed in LMCA, proximal LAD (or equivalent), bifurcation
Phase 2 bridge study for urgent surgery early after DES Exclusion criteria Inclusion criteria • 12 months in the case of high-risk of ST: • stent implantation due to an ACS • diabetes • renal insufficiency • severe LV dysfunction • DES in LMCA, proximal LAD, bifurcation · Allergy to tirofiban – eptifibatide · Thrombocytopenia <100.000 · Stroke < 30 days or prior ICH · Intracranial disease · Uncontrolled hypertension · Unable to sign consent form Patients within 6-12 months of DES implantation + high-risk for surgical bleeding, “so that the surgeon would not operate on clopidogrel” surgery Stop Plavix Start bridge Stop bridge Resume Bridge** Resume Plavix 300+75 mg*** • Aspirin continued throughout • Low-dose LMWH for DVT prevention T Day -5 -4 -3 -2 -1 4h* 0 4h follow-up until discharge *8h in pts with eGFR <30 ml/min **if oral admin not possible *** as soon as oral admin possible Primary EP: the composite of Death, MI, stent thrombosis, haemostatic reoperation Savonitto S et al, Br J Anaesth. 2010 Jan 3. [Epub ahead of print]
Antagonisti della Gp IIb/IIIa farmacocinetica 100 Tirofiban Abciximab 80 Eptifibatide 60 % aggregazione piastrinica 40 20 0 6 12 18 24 30 36 oredalla sospensione dell’infusione Mousa et al. Drugs Future 1996;21: 1141-54
Initial experience : 30 patients-8 cardiac surgery, 6 urinary tract , 10 gastroenteric surgery, 5 other surgery- No MACE ( death, MI, stroke )- 1 TIMI major bleeding- 8 patients required blood transfusion ( 6 before surgery for anemia, 2 post-operatively for proctorrhagy ). Savonitto S et al, Br J Anaesth. 2010 Jan 3. [Epub ahead of print]
Delay from DES implantation to surgery Updated October 2, 2009 Median 3 months, range 12 days – 12 months Cardiovascular N= 13 Non Cardiovascular N= 27 12 months N° 10 17 20 28 29 30 34 36 37 38 39 40 <6 months N=30 6-12 months N=10
Phase 2 bridge study For urgent surgery early after DES: current status PATIENTS ENROLLED 40 cardiac 13 urinary tract 6 gastrointestinal 14 mixed surgery 7 PRIMARY ENDPOINT* 0 (97.5% C.I. 0-8.81) BLEEDING** EVENTS major 1 minor 3 transf. 9 SEVERE§ THROMBOCITOPENIA 1 * The composite of death+MI+stent thrombosis+haemostatic reoperation **Bleeding according to TIMI criteria: major means Hb decrease >5 g/dL, minor means Hb decrease >3 but <5 g/dL, after correction for transfusion (1 g ofHb for each U transfused); § platelet count <20,000.
550 patients undergoing non-cardiac surgery after stent implantation 50% 14% 4% MACE= death,MI,stent thrombosis,repeat revascularization
Combined events ( death,MI,stent thrombosis as a function of time )
695 surgeries in 481 patients out of 12.794 with DES implantation (5.4%): Incidence as a function of time from intervention Stent thrombosis Death , MI , stent thrombosis Events as stratified by time from PCI to surgery
Early surgery after stent implantation: High risk after discontinuation of dual antiplatelet therapy October
Early surgery after stent implantation: risk stratification for stent thrombosis
Antagonisti della Gp IIb/IIIa tollerabilità Studio farmaco sanguinamenti maggiori (TIMI) p trattamento placebo <0,001NS 0,043 NS NS <0,001 EPIC EPILOG CAPTURE EPISTENT IMPACT II PURSUIT Abciximab Abciximab Abciximab Abciximab Eptifibatide Eptifibatide 14% 2,0% 3,8% 1,5% 5,1% 3,0% 6,6% 3,1% 1,9% 2,2% 4,8% 1,3% Lamifiban 0,5% 2,4% 0,4% 1,4% 1,5% 2,1% 0,4% 0,8% PARAGON NS NS NS NS RESTORE PRISM PRISM-PLUS Tirofiban Tirofiban Tirofiban adapted from Blankenship et al. Am Heart J Oct 1999; 138: S287-S296
F.G. , woman , 77 years old • Type II diabetes, hypertension • October 08 , NSTE-ACS • Coronary arteriography : prox LAD 80% • PCI ( Cypher 3-18 ) • Discharged with ASA 75 mg, Plavix 75mg, Atorvastatin 20 mg, Metformin 1500 mg, Ramipril 10 mg.
December 2008: recurrent fever, urine culture analysis positive for Escherichia Coli . Treated with antibiotics • January 2009 : hospitalized because of abdominal pain , colonoscopy : colo-vesical fistula . • Surgery needed ( colon resection, vesical suture ).
Stent thrombosis is observed in about 2 per cent of patients after 1 year of implantation , but it results in death in more than 20% of cases and in death and MI in nearly 90% of cases.
Problems : • Discontinuation of clopidogrel ? • Surgery on clopidogrel ?
Problems : • Discontinuation of clopidogrel ? ( risk of stent thrombosis )
BUT: 161 cases of late-very late definite stent thrombosis published in the literature
Problems : • Discontinuation of clopidogrel ? ( risk of stent thrombosis ) • Surgery on clopidogrel ? ( surgeon’s objections: 1) risk of important bleeding 2) no absorption of the drug in the perioperative period.
CF.V. 77 years old- Clopidogrel discontinued 5 days before surgery starting January 31st.- Tirofiban infusion ( dose used for NSTE-ACS no heparin )- February 5th: surgery ( colon resection, vesical suture ). Tirofiban resumed until intestinal canalization ( February 9th when clopidogrel LD 300 mg and aspirin were given and Tirofiban discontinued )- No clinical complications , no major bleeding . Pre-op Hb 10.3g/dl (Transfusion 2U) Hb post-op (February 9th) 10.2g/dl